尺寸阈值作为典型卵巢皮样病变恶变风险指标:范围综述
本范围综述系统检索截至2024年1月14日的文献,纳入25项研究共15,295个皮样囊肿,其中215个发生恶变;46/173(27%)恶变病灶小于10 cm,提示现行O-RADS 10 cm阈值可能将超过25%的恶变囊肿归为「几乎肯定良性」。
要点
- 46/173(27%)恶变皮样囊肿小于10 cm,现行10 cm O-RADS阈值可能将超过25%的恶变归为「几乎肯定良性」。
- 实性强化成分报告较少,但描述到时均大于1 cm。
- 作者认为可考虑对O-RADS 2皮样囊肿进行监测,并修改MRI O-RADS中关于实性成分的注意事项推荐。
核心结论
- 超过25%的恶变皮样囊肿可能被现行10 cm O-RADS恶性风险阈值归为「几乎肯定良性」。
研究设计与样本
- 范围综述,遵循PRISMA-ScR指南,检索MEDLINE、Embase、Scopus和Cochrane图书馆从建库至2024年1月14日,并检索灰色文献和纳入研究的参考文献;纳入25项研究(6篇病例报告和19项回顾性研究),共15,295个皮样囊肿,其中215个病灶发生恶变,以病理为参考标准。
关键影像表现/征象
- 报告恶变皮样囊肿尺寸的研究中,病灶大小范围为1至32 cm。
- 46/173(27%)的恶变病灶测量小于10 cm。
- 实性强化成分报告不频繁,但描述到时均测量大于1 cm。
诊断标准与关键数值
- 现行O-RADS采用10 cm阈值对典型卵巢皮样囊肿进行恶性风险分层,该阈值基于专家共识而非客观临床数据分析。
- 46/173(27%)的恶变皮样囊肿小于10 cm,可能被现行10 cm O-RADS阈值归为「几乎肯定良性」。
临床应用与阅片要点
- 作者认为对O-RADS 2皮样囊肿进行监测可能提高敏感度。
- 作者认为当其他方面典型的良性皮样囊肿存在潜在实性成分时,修改MRI O-RADS中关于请妇科肿瘤医生会诊的注意事项推荐可能是合适的。
局限性
- 数据合成以定性综述形式提供。
- 纳入研究包括6篇病例报告和19项回顾性研究。
- 实性强化成分报告不频繁。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: The O-RADS malignancy risk stratification of typical ovarian dermoid cysts by using a 10 cm threshold is based on expert consensus rather than analysis of objective clinical data. This comprehensive scoping review consolidated all currently available studies evaluating typical benign ovarian dermoid cyst size and risk for malignant transformation.
METHODS: A systematic review of MEDLINE, Embase, Scopus and the Cochrane library was performed from inception to January 14, 2024, using PRISMA-ScR guidelines. A grey literature search and forward searching of reference lists from included studies were performed. Case reports and case series evaluating dermoid cyst size and malignant transformation as defined by a pathological reference standard were included. Data synthesis was provided as a qualitative review of the existing literature.
RESULTS: Twenty-five studies were included in qualitative synthesis comprising 6 case reports and 19 retrospective studies with a total of 15,295 dermoid cysts. Of these, 215 lesions demonstrated malignant transformation. Studies reporting dermoid size with malignant transformation ranged from 1 to 32 cm with 46/173 (27%) total malignant transformation lesions measuring < 10 cm. Solid enhancing components were infrequently reported but all measured > 1 cm when described.
CONCLUSION: More than 25% of dermoid cysts with malignant transformation may be classified as "almost certainly benign" with the current 10 cm O-RADS malignancy risk threshold. Although surveillance of O-RADS 2 dermoid cysts may improve sensitivity, modifying a caveat recommendation for MRI O-RADS +/- gyn-oncologist referral when potentially solid components are present in otherwise typically benign dermoid cysts may be appropriate.
引用
- Jordan H, Low G, Wilson MP, et al. Size threshold as a risk for malignant transformation in typical ovarian dermoid lesions: a scoping review. Abdom Radiol (NY). 2024. PMID: 39707031. doi:10.1007/s00261-024-04751-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。